UNSPSC 51111764: Vinepidine

This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H56N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, W3375J6V0Y chemically known as vincaleukoblastine, 4'-deoxy-22-oxo-, (4'.alpha.)- but generally known as vinepidine, which bears US NIH Compound Identifier 125688. European Medicines Agency schedules Vinepidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00062MIG.

UNSPSC 51111764 Vinepidine is a Commodity code covering specialized pharmaceutical products, though recent state and local procurement activity under this code shows minimal direct alignment with the code's nominal scope. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC for antibiotic supply (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets) over a three-year term with quarterly deliveries, while Seminole County, Florida solicited Naloxone and Safe Drug Deactivation Systems through competitive IFB. Neither opportunity involves vinepidine procurement. State and local buyers under this code appear to include state health departments and county health authorities purchasing through cooperative purchasing vehicles and direct IFB processes, though the recent record does not demonstrate sustained activity specific to vinepidine itself.

Recent activity centers on Illinois and Florida, with procurement mechanisms favoring cooperative purchasing agreements (MMCAP) and traditional IFB notice types. The Illinois award was completed as a piggyback contract under an existing consortium vehicle with no set-asides or domestic-product preferences applied, while the Seminole County procurement required E-Verify compliance, workers' compensation insurance, and drug-free workplace certification. The limited recent opportunities tagged to this code suggest either sparse demand for vinepidine specifically at the state and local level or systematic miscoding of pharmaceutical acquisitions; prospecting firms should verify actual procurement patterns through cooperative purchasing catalogs and direct outreach to state Medicaid programs and county health authorities before treating the code as an active market segment.